Avacopan

MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen's Tavneos' steroid-sparing ability and remission times as impressive

Retrieved on: 
Wednesday, March 1, 2023
MPA, REACH, Safety, GPA, Amgen, Receptor (biochemistry), Maintenance, Perception, FDA, Prognosis, Patient, Inflammation, AAV, Steroid, ANCA, Physician, Pharmaceutical industry, Dietary supplement, Avacopan

NEWTON, Mass., March 1, 2023 /PRNewswire/ -- Tavneos (avacopan), a C5aR inhibitor, is a first-in-class FDA-approved steroid-sparing adjunctive therapy for severe, active microscopic polyangiitis (MPA) or granulomatosis polyangiitis (GPA), two forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). AAV is a chronic organ-threatening autoimmune condition marked by inflammation of small-to-medium blood vessels.

Key Points: 
  • AAV is a chronic organ-threatening autoimmune condition marked by inflammation of small-to-medium blood vessels.
  • To access REACH's AAV MarketVue® Report, visit https://reachmr.com or contact us at [email protected] .
  • Physicians are eager for steroid-sparing treatments, which explains the positive feedback about avacopan's ability to get patients off steroids in as quickly as a month.
  • Meghana Pandit, REACH Analyst: "To supplant current therapies, newer agents must be able to induce long-term remission, reduce corticosteroid burden, and prevent relapses."

ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis

Retrieved on: 
Tuesday, July 6, 2021
Medical specialties, Clinical medicine, Medicine, Food and Drug Administration, Hidradenitis suppurativa, Vasculitis, Hidradenitis, Prescription Drug User Fee Act, Avacopan

The FDA has indicated that the filing constitutes a major amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7, 2021.

Key Points: 
  • The FDA has indicated that the filing constitutes a major amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7, 2021.
  • The NDA is primarily based on data from the Phase III ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis.
  • The ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries.
  • ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS).

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

Retrieved on: 
Wednesday, June 30, 2021
Legal, Professional services, Medical specialties, Medicine, Clinical medicine, Avacopan, Class action, Vasculitis, Chapel Hill Consensus Conference

If you are a shareholder who suffered a loss, click here to participate.

Key Points: 
  • If you are a shareholder who suffered a loss, click here to participate.
  • Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

Retrieved on: 
Thursday, June 24, 2021
Medical specialties, Medicine, Clinical medicine, Avacopan, Vasculitis, Class action

Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).

Key Points: 
  • Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • Glancy Prongay & Murray LLP, Los Angeles

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ChemoCentryx, AcelRx, Ocugen, and Tarena and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 24, 2021
Medical specialties, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Ethers, Sufentanil, Vasculitis, Avacopan, Fentanyl

The FDA also raised serious safety concerns with avacopan for the treatment of ANCA-associated vasculitis.

Key Points: 
  • The FDA also raised serious safety concerns with avacopan for the treatment of ANCA-associated vasculitis.
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • For more information on the Tarena class action go to: https://bespc.com/cases/TEDU
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Medicine, Clinical medicine, Avacopan, Vasculitis, Class action

Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).

Key Points: 
  • Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders

Retrieved on: 
Wednesday, June 9, 2021
Legal, Professional services, Medical specialties, Medicine, Clinical medicine, Rheumatology, Avacopan, ANCA, Vasculitis, Autoimmunity

ChemoCentryx is a biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer.

Key Points: 
  • ChemoCentryx is a biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer.
  • ChemoCentryx's lead drug candidate is avacopan, which the Company describes as a "potential first-in-class, orally-administered molecule for the treatment of patients with ANCA vasculitis."
  • If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or [email protected] , or via our Shareholder Information Form .
  • Robbins LLP is a nationally recognized leader in shareholder rights law.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

Retrieved on: 
Monday, June 7, 2021
Medical specialties, Medicine, Clinical medicine, Avacopan, Vasculitis, Limited liability partnership, Glancy, AAV, Class action

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles